All News
A new report in La Merie Publishing describes and analyzes cadherin 17 as a promising target for drug development, which has largely gone unexploited.
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics’ available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.
Biohaven Pharma’s NDA for its nasal spray zavegepant was accepted by the FDA, while Phase III results for its drug troriluzole to treat spinocerebellar ataxia were disappointing.
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
A small research study published in Jama shows people with a lower body mass index (BMI) tended to maintain immunity against COVID-19 longer.
The crisis caused by the shutdown of one plant is a stark reminder of critical supply chain issues in other sectors, including the pharmaceutical industry.
Regeneron Pharmaceuticals shared positive results from its Phase III trial of an evinacumab for children with homozygous familial hypercholesterolemia.
Vir Biotechnology terminated a two-year-old COVID-19-related antibody collaboration with Wuxi Biologics that included sotrovimab, which lost EUA in the U.S. earlier this year.
Based on topline data, Pfizer stated that three doses of the COVID-19 vaccine met all immunobridging criteria required for EUA. The FDA’s advisory committee will meet June 15 to discuss the matter.
Sunday night, U.S. health authorities announced that they may have found the third documented case of monkeypox in a patient in South Florida.
Elicio Therapeutics published data on the preprint server bioRxiv, describing preclinical research into its cancer vaccine that shows a lot of promise.
Alnylam Pharmaceuticals shared 18-month results from its phase III Helios-A clinical study demonstrating that vutrisiran improves clinical cardiac symptoms in patients with hATTR.
Two experimental drugs from Seres Therapeutics and Vera Therapeutics celebrate clinical trial wins in hard-to-treat disease areas.
The compact and portable nasal spray means it can be used directly before an anxiety-provoking trigger or at the beginning of an episode.
The approval marks the first for EoE, a chronic, progressive type 2 inflammatory disease that damages the eosinophilic esophagitis and prevents it from working properly.
The Zymeworks Board of Directors has rejected an acquisition proposal from activist investor All Blue Falcons FZE, calling the attempt “opportunistic.”
Recently, researchers have characterized the biological significance of gene fusions as a potential molecular targeted therapy owing to their high specificity and selectivity towards the cancer cell.
Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.